Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Helen Boucher

Transplant/Immunocompromised States · Tufts

View

Dr. Sara Dong

Transplant/Immunocompromised States · Boston Children's Hospital

View

Dr. Chris Beyrer

Global Health · Duke University

View

Dr. Lance Okeke

HIV/AIDS Medicine · Duke University

View

Dr. Raphael J. Landovitz

HIV/AIDS Medicine · UCLA

View

Dr. Keith Kaye

General ID · RU

View

Dr. Aniruddha Hazra

HIV/AIDS Medicine · UCMC

View

Dr. Rochelle Walensky

General ID · Harvard Medical School

View

Dr. Kelly Dooley

Mycobacterial Disease · Vanderbilt

View

Dr. Erin Bonura

General ID · OHSU

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Infections After Kidney Transplantation From Donors With HIV to Recipients With HIV.

    Mar 17, 2026DOI: 10.1093/cid/ciaf656Journal ArticleCID

    Written by: Elizabeth C ArantThibaut Davy-MendezTao LiangMoreno RodriguesCynthia L GayMeenakshi M RanaRachel Friedman-MoracoAlexander GilbertPeter StockSapna A MehtaShikha MehtaValentina StosorMarcus R PereiraMichele I MorrisJonathan HandSaima AslamMaricar MalinisGhady HaidarCatherine B SmallCarlos A Q SantosJoanna SchaenmanJohn W BaddleyDavid WojciechowskiEmily A BlumbergKarthik RangannaOluwafisayo AdebiyiNahel EliasJose A Castillo-LugoEmmanouil GiorgakisSenu ApewokinMegan MorsheimerChristian van DeldenOriol ManuelNicolas J MuellerDionysios NeofyotosAaron A R TobianAllan MassieDorry L SegevWilliam WerbelChristine M Durand

    Find these authors on Roon

    SM

    Dr. Sapna A. Mehta

    Transplant/Immunocompromised States · NYU Langone

    JS

    Dr. Joanna Schaenman

    Transplant/Immunocompromised States · UCLA

    Summary

    BACKGROUND: Kidney transplantation (KT) from donors with human immunodeficiency virus (HIV-1) to recipients with HIV (HIV D+/R+) is noninferior to KT from donors without HIV (HIV D-/R+) with regard to safety. However, there may be differences in posttransplant infections.METHODS: We performed a secondary analysis of the HOPE in Action KT Study (NCT02602262) comparing the time to first clinically relevant infection within 24 months posttransplantation in 99 HIV D+/R+ versus 99 HIV D-/R+. Secondary outcomes included incidence rates, infection-related death, and timing of clinically relevant infection, each stratified by donor HIV status.RESULTS: The cumulative incidence of a clinically relevant infection at 24 months posttransplantation was 73.8% (95% confidence interval for HIV D+/R+ versus 64.7% (95% CI: 53.0%-73.4%) for HIV D-/R+. Comparing time to first clinically relevant infection in HIV D+/R+ versus HIV D-/R+, the adjusted hazard ratio (aHR) was 1.44 (95% CI: 1.01-2.04) at 24 months posttransplantation; for infections associated with hospitalization, the aHR was not significantly higher (1.21 [95% CI: .78-1.86). There were no significant differences in the number of infections, death from infection, duration, or site of infection between HIV D+/R+ versus HIV D-/R+, though viral infections were numerically more common in HIV D+/R+ (40% vs 35%).CONCLUSIONS: Although there was a statistically significant association between receipt of a kidney from a donor with HIV and time to first clinically relevant infection in the 24 months posttransplantation, there were no differences in infections associated with hospitalization. These data are overall reassuring as this emerging practice expands into clinical care. Clinical Trials Registration. NCT02602262.
    JSDr. Joanna Schaenman

    Dr. Joanna Schaenman

    Infectious Disease · Transplant/Immunocompromised States
    University of California, Los Angeles
    joannas
    Los Angeles, CA, USA